EA202092492A1 - Способ лечения и композиции, содержащие двойной ингибитор киназ pi3k дельта-гамма и кортикостероид - Google Patents

Способ лечения и композиции, содержащие двойной ингибитор киназ pi3k дельта-гамма и кортикостероид

Info

Publication number
EA202092492A1
EA202092492A1 EA202092492A EA202092492A EA202092492A1 EA 202092492 A1 EA202092492 A1 EA 202092492A1 EA 202092492 A EA202092492 A EA 202092492A EA 202092492 A EA202092492 A EA 202092492A EA 202092492 A1 EA202092492 A1 EA 202092492A1
Authority
EA
Eurasian Patent Office
Prior art keywords
corticosteroid
delta
gamma
treatment
dual pi3k
Prior art date
Application number
EA202092492A
Other languages
English (en)
Inventor
Сваруп Кумар Венката Сатья Ваккаланка
Срикант Висванадха
Original Assignee
Ризен Фармасьютикалз Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ризен Фармасьютикалз Са filed Critical Ризен Фармасьютикалз Са
Publication of EA202092492A1 publication Critical patent/EA202092492A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Настоящее изобретение относится к способу лечения аутоиммунных, респираторных и/или воспалительных заболеваний или состояний, например астмы, ХОБЛ, ревматоидного артрита и идиопатического фиброза легких (ИФЛ). Предложенный способ включает введение двойного ингибитора PI3K дельта и гамма и кортикостероида. Настоящее изобретение также относится к фармацевтическим композициям, содержащим двойной ингибитор PI3K дельта и гамма и кортикостероид.
EA202092492A 2014-09-03 2015-09-03 Способ лечения и композиции, содержащие двойной ингибитор киназ pi3k дельта-гамма и кортикостероид EA202092492A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN4287CH2014 2014-09-03

Publications (1)

Publication Number Publication Date
EA202092492A1 true EA202092492A1 (ru) 2021-07-30

Family

ID=54249540

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201790379A EA038527B1 (ru) 2014-09-03 2015-09-03 Способ лечения респираторного заболевания или состояния, композиции и наборы, содержащие двойной ингибитор киназ pi3k дельта-гамма и кортикостероид
EA202092492A EA202092492A1 (ru) 2014-09-03 2015-09-03 Способ лечения и композиции, содержащие двойной ингибитор киназ pi3k дельта-гамма и кортикостероид

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201790379A EA038527B1 (ru) 2014-09-03 2015-09-03 Способ лечения респираторного заболевания или состояния, композиции и наборы, содержащие двойной ингибитор киназ pi3k дельта-гамма и кортикостероид

Country Status (25)

Country Link
US (2) US10786504B2 (ru)
EP (2) EP3188759B1 (ru)
JP (3) JP6559775B2 (ru)
KR (1) KR20170044203A (ru)
CN (2) CN113332439A (ru)
AU (2) AU2015310545B2 (ru)
BR (1) BR112017004163A2 (ru)
CA (1) CA2958988A1 (ru)
CL (1) CL2017000512A1 (ru)
CY (1) CY1123075T1 (ru)
DK (1) DK3188759T3 (ru)
EA (2) EA038527B1 (ru)
ES (1) ES2802202T3 (ru)
HR (1) HRP20200968T1 (ru)
HU (1) HUE049480T2 (ru)
IL (2) IL250918B (ru)
LT (1) LT3188759T (ru)
MX (2) MX2017002878A (ru)
PH (1) PH12017500378A1 (ru)
PL (1) PL3188759T3 (ru)
PT (1) PT3188759T (ru)
RS (1) RS60450B1 (ru)
SG (2) SG11201701499YA (ru)
SI (1) SI3188759T1 (ru)
WO (1) WO2016035032A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113557020A (zh) * 2018-09-14 2021-10-26 瑞真药业公司 包含crac抑制剂和皮质类固醇的组合物及其使用方法
CN116492351B (zh) * 2023-03-13 2024-03-12 香港大学深圳医院 氯替泼诺在制备治疗早发性卵巢功能不全及卵巢响应匮乏药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018774A (en) 1976-02-13 1977-04-19 E. R. Squibb & Sons, Inc. Steroidal [16α,17-d]isoxazolidines
SE8106165L (sv) 1981-10-19 1983-04-20 Atlas Copco Ab Forfarande for bergbultning och bergbult
GB0415747D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
KR101897881B1 (ko) 2008-01-04 2018-09-12 인텔리카인, 엘엘씨 특정 화학 물질, 조성물 및 방법
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2010002804A2 (en) 2008-07-01 2010-01-07 Wisconsin Alumni Research Foundation Method and compositions for inhibition of double stranded dna viruses
SG174483A1 (en) * 2009-03-24 2011-10-28 Univ Singapore Use of artemisinin derivatives for the treatment of asthma and chronic obstructive pulmonary disease (copd)
CN102482318B (zh) 2009-09-11 2015-11-25 奇斯药制品公司 异噁唑烷衍生物
PL2496567T3 (pl) 2009-11-05 2018-01-31 Rhizen Pharmaceuticals S A Nowe benzopiranowe modulatory kinazy
CA2781314A1 (en) * 2010-01-28 2011-08-04 The Johns Hopkins University Compositions and methods for reversing corticosteroid resistance or treating respiratory infections
ES2773079T3 (es) * 2010-02-08 2020-07-09 Shenzhen Evergreen Therapeutics Co Ltd Métodos para el uso de progestágeno como sensibilizador de glucocorticoides
ES2637113T3 (es) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
EP2716648B1 (en) 2011-03-15 2017-06-14 CHIESI FARMACEUTICI S.p.A. Isoxazolidine derivatives
SG194718A1 (en) * 2011-05-04 2013-12-30 Rhizen Pharmaceuticals Sa Novel compounds as modulators of protein kinases
SE540189C2 (en) 2012-05-22 2018-04-24 Epiroc Canada Inc Rock bolt and method of installing the rock bolt and a protecting sleeve for it
JP6434416B2 (ja) * 2012-11-08 2018-12-05 ライゼン・ファーマシューティカルズ・エスアー ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物
CN204282361U (zh) 2014-12-11 2015-04-22 湖南科技大学 一种带钢丝网的软土地基充气锚杆

Also Published As

Publication number Publication date
CN106714842A (zh) 2017-05-24
WO2016035032A1 (en) 2016-03-10
LT3188759T (lt) 2020-07-10
AU2021200051A1 (en) 2021-02-18
AU2015310545A1 (en) 2017-03-16
CA2958988A1 (en) 2016-03-10
JP2017525739A (ja) 2017-09-07
CN113332439A (zh) 2021-09-03
HUE049480T2 (hu) 2020-09-28
IL250918A0 (en) 2017-04-30
PH12017500378A1 (en) 2017-07-17
SI3188759T1 (sl) 2020-08-31
BR112017004163A2 (pt) 2017-12-05
CL2017000512A1 (es) 2017-11-03
JP6559775B2 (ja) 2019-08-14
MX2017002878A (es) 2017-05-30
AU2015310545B2 (en) 2020-10-22
DK3188759T3 (da) 2020-06-29
IL250918B (en) 2021-02-28
HRP20200968T1 (hr) 2020-10-16
RS60450B1 (sr) 2020-07-31
KR20170044203A (ko) 2017-04-24
MX2020011472A (es) 2020-12-07
NZ729419A (en) 2021-08-27
PT3188759T (pt) 2020-07-02
JP2019172708A (ja) 2019-10-10
EA038527B1 (ru) 2021-09-10
US20210030757A1 (en) 2021-02-04
US20170281630A1 (en) 2017-10-05
CN106714842B (zh) 2021-07-02
SG10202100596SA (en) 2021-02-25
JP2021191804A (ja) 2021-12-16
US10786504B2 (en) 2020-09-29
ES2802202T3 (es) 2021-01-15
EA201790379A1 (ru) 2017-06-30
PL3188759T3 (pl) 2020-11-02
CY1123075T1 (el) 2021-10-29
IL280686A (en) 2021-03-25
EP3701950A1 (en) 2020-09-02
EP3188759A1 (en) 2017-07-12
SG11201701499YA (en) 2017-03-30
EP3188759B1 (en) 2020-04-01

Similar Documents

Publication Publication Date Title
EA201590721A1 (ru) Фармацевтические композиции, содержащие ингибитор pde4 и ингибитор pi3-дельта или двойной ингибитор pi3-дельта-гамма киназы
PH12018500086A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
PH12018500907A1 (en) Inhibitors of ret
PH12017500072A1 (en) Spirocycloheptanes as inhibitors of rock
NZ729603A (en) Heteroaryl compounds as btk inhibitors and uses thereof
EA201792619A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
GEP20186921B (en) Pyrazolopyridines and pyrazolopyrimidines
HK1253537A1 (zh) 吡咯並嘧啶激酶抑制劑的藥用鹽、物理形態和組合物及其製備方法
MX2021003792A (es) Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2.
MX2015008741A (es) Ftalazinonas e isoquinolinonas como inhibidores de cinasa rho.
EA201692437A1 (ru) Комбинация
IL255109A0 (en) New dihydropyridoisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
HK1258996A1 (zh) 新型fyn激酶抑制劑的方法、組合物以及用途
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2017003216A (es) Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.
HK1247926A1 (zh) 四氫-n，n-二甲基-2，2-二苯基-3-呋喃甲胺鹽酸鹽的晶型，製備這樣晶型的方法，及其藥物組合物
MX2017001103A (es) Derivados de indolizina que son aplicables a enfermedades neurodegenerativas.
EA201890364A1 (ru) СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t
IN2014CH00840A (ru)
CY1123075T1 (el) Μεθοδος αγωγης και συνθεσεις που περιλαμβανουν εναν διπλο αναστολεα κινασης ρι3κ δελτα-γαμα και ενα κορτικοστεροειδες
EA201692227A1 (ru) Производные сложных аминоэфиров
CR20200183A (es) Compuestos inhibidores de tirosina cinasa de bruton (btk)